Walleye Capital
TXG icon

Walleye Capital’s 10x Genomics TXG Stock Holding History

Walleye Capital’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,800
Closed -$94.6K – 5004
2025
Q4 		$94.6K Buy
+5,800
New +$87.6K ﹤0.01% 3898
2025
Q1 		– Sell
-1,300
Closed -$18.7K – 5157
2024
Q4 		$18.7K Sell
1,300
-7,300
-85% -$115K ﹤0.01% 4514
2024
Q3 		$194K Sell
8,600
-42,500
-83% -$879K ﹤0.01% 4029
2024
Q2 		$994K Buy
51,100
+50,400
+7,200% +$1.32M ﹤0.01% 2855
2024
Q1 		$26.3K Sell
700
-4,700
-87% -$207K ﹤0.01% 4852
2023
Q4 		$302K Sell
5,400
-500
-8% -$21.8K ﹤0.01% 3364
2023
Q3 		$243K Sell
5,900
-3,000
-34% -$156K ﹤0.01% 3399
2023
Q2 		$497K Buy
8,900
+6,700
+305% +$363K ﹤0.01% 2445
2023
Q1 		$123K Sell
2,200
-3,600
-62% -$168K ﹤0.01% 2814
2022
Q4 		$211K Buy
+5,800
New +$190K ﹤0.01% 2009

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's TXG Position: Q1 2026 in Review

Walleye Capital sold out of 10x Genomics (TXG) in Q1 2026, closing a stake of 1,577 shares — an estimated $25.7K sold.

Walleye Capital first reported a position in TXG in Q2 2020 and held it in 13 quarters. The position peaked at $4.19M in Q4 2024. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Walleye Capital reported no remaining 10x Genomics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 1,577 10x Genomics shares in Q1 2026, an estimated $25.7K.
  • Walleye Capital first reported a position in 10x Genomics in Q2 2020 and held it in 13 quarters.
  • Walleye Capital's 10x Genomics position peaked at $4.19M in Q4 2024.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.